Anupam Rasayan India Limited has informed the Exchange about acquisition.
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 0.8 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Anupam Rasayan's board, on February 12, 2026, approved and confirmed the acquisition of Doriath S.à r.l. (100% stake, completed on February 10, 2026) and 15% in Batam S.à r.l., both Luxembourg-based entities set up as intermediaries for the larger acquisition of Monitchem Kansas S.à r.l. and its subsidiaries (Kansas HoldCo Inc., Kansas HoldCo 1 Inc., and Jayhawk Fine Chemicals Corporation) from CABB Europe GmbH, under a Sale and Purchase Agreement signed on December 9, 2025. The company is raising USD 20 million via Credit Facilities from Altis XII Pte. Ltd. (through Doriath) and USD 30 million as an External Commercial Borrowing from Axis Bank IBU GIFT City to fund the deal. Total shareholder-approved outlay for this acquisition is up to Rs. 4,500 crores. Various charges and pledges over company assets and shares (including in Tanfac Industries Limited and Doriath) are being created as security for these facilities.
This is a material acquisition expanding Anupam Rasayan's global footprint into specialty chemicals via the CABB/Monitchem target group, but it also brings significant debt and asset encumbrances that could pressure leverage and dilute near-term returns. Shareholders should watch for completion timelines and any impact on profitability once the target is consolidated.